Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | NNMT | P40261 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515282 | 1.00 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12SCN9ASCN5A | |
| SCHEMBL23882273 | 0.77 | FGFR1 (0.38) | FGFR1FGFR4SLC22A12SCN9ASCN5A | |
| SCHEMBL515318 | 0.75 | GPR119 (0.56) | — | |
| SCHEMBL14806597 | 0.74 | FGFR1 (0.38) | FGFR1FGFR4SLC22A12SCN9ASCN5A | |
| SCHEMBL14806596 | 0.74 | FGFR1 (0.38) | FGFR1FGFR4SLC22A12SCN9ASCN5A | |
| SCHEMBL29950127 | 0.73 | PIK3CD (0.41) | — | |
| SCHEMBL23897580 | 0.73 | PIK3CD (0.41) | — | |
| SCHEMBL17406889 | 0.72 | ACACB (0.43) | FGFR1FGFR4SLC22A12SCN9AKCNH2 | |
| SCHEMBL17394745 | 0.71 | GPR119 (0.46) | — | |
| SCHEMBL1941046 | 0.71 | ACACB (0.41) | FGFR1FGFR4SLC22A12SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | GPR119, GPR4, GPR84 | FGFR1 77/4885FGFR4 103/4885SLC22A12 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.